{"id":134179,"title":"Share Talk Weekly Small Cap Movers & Shakers, Saturday 28th March 2026","publisher":"Share Talk","author":"sharetalk","published":"2026-03-28T11:52:55+00:00","modified":"2026-03-28T11:56:57+00:00","canonical_url":"https://www.share-talk.com/share-talk-weekly-small-cap-movers-shakers-saturday-28th-march-2026/","markdown_url":"https://www.share-talk.com/share-talk-weekly-small-cap-movers-shakers-saturday-28th-march-2026.md","json_url":"https://www.share-talk.com/share-talk-weekly-small-cap-movers-shakers-saturday-28th-march-2026.json","category":"Blogs","categories":["Blogs","Small Cap Review","Technology","Technology, Media & Telecoms"],"tags":["Aim All Share","FTSE 100","Immupharma","Metals One","MobilityOne","Quadrise PLC","SkinBioTherapeutics","Small-cap markets","Strait of Hormuz"],"featured_image":"https://i0.wp.com/www.share-talk.com/wp-content/uploads/2026/03/Stencil-Google-Chrome-2023-04-19-at-2.47.43-PM.webp?fit=1231%2C615&quality=80&ssl=1","format":"news","language":"en-GB","content":"The AIM All-Share slipped slightly on the week and is now down around 7% year-to-date, underlining the pressure on smaller companies. In contrast, the FTSE 100 closed the week at 9,967, slipping just 5 points (-0.05%) on Friday but still finishing slightly higher over the week.\n\nInvestor sentiment remained cautious, with markets continuing to track developments in the Middle East. Oil prices were a key focus, with Brent crude rising for a third consecutive session and moving back above $100 per barrel. Analysts say persistent doubts over a near-term US-Iran deal, along with ongoing military tensions, are keeping supply risks elevated, particularly around the Strait of Hormuz.\n\n### Small-cap markets: big winners, sharp losses and a volatile backdrop\n\nIt has been a turbulent week for small-cap stocks, with sharp gains and heavy losses reflecting both company-specific developments and a broader market still dominated by geopolitical uncertainty.\n\nThe standout performer was **Quadrise PLC**, whose shares surged close to** 80%** as investors focused on the commercial potential of its MSAR fuel technology. The product, which blends residual oil with water to create a lower-cost, lower-emission alternative to conventional bunker fuel, is gaining traction at a time when shipping operators face rising fuel costs and increasing environmental pressure.\n\nElsewhere, gains were equally dramatic in parts of the market. **MobilityOne** rose more than **400%** as progress on a long-delayed corporate transaction brought forward the prospect of a sizeable cash inflow. **SkinBioTherapeutics** recovered strongly, up 45% over the week, after reassuring investors over its cash position despite an ongoing accounting review. Meanwhile, **Metals One** advanced** 31%** as developments around the Vantage Goldfields deal continued to move in a positive direction.\n\n**ImmuPharma** also moved higher, gaining **10.3% to 5.015p**, after receiving a positive initial report on its UK patent application for its **P140 autoimmune programme**. The company has also completed a supporting study and continues to highlight **strong interest from potential licensing partners**, following its recent **£6.5 million fundraising**.\n\nMeanwhile, **Hargreaves Services** gained **7.14% to 785p** after launching a **tender offer at 850p per share**, an increase from the previously indicated 750p, and raising the total buyback size to **£20 million** following further asset disposals.\n\nDespite these pockets of strength, the broader backdrop remains challenging. The **AIM All-Share** slipped slightly on the week and is now down around 7% year-to-date, underlining the pressure on smaller companies. In contrast, the **FTSE 100** held relatively steady, reflecting its more defensive composition, though trading has been highly volatile.\n\n### Decliners: delays, funding pressure and restructuring\n\nOn the downside, several companies saw steep declines. **Distil** was among the hardest hit, falling around 40% after warning that revenues would miss expectations and highlighting an immediate funding challenge driven by distribution issues. **Premier African Minerals** also endured another difficult week, dropping 37% as it raised funds at a deeply discounted price to support ongoing operations. **MISSION Group** fell 28% after reporting a swing to a significant loss, driven largely by impairment charges and weaker client demand.\n\n**Switch Metals**, dropping **24.1% to 11p** after confirming delays to its maiden resource estimate for the Issia project, with further assay work and modelling still ongoing. **Parkmead Group** slipped **8.33% to 22p**, despite reporting a stronger cash position of **£16.1 million**, as investors appeared to take a cautious view on the timing of future returns linked to North Sea asset sales. **Seeing Machines** fell **4.84% to 2.95p**, even as it pointed to improving margins and a path to EBITDA profitability later in 2026. The decline reflects ongoing concerns around revenue contraction and an upcoming refinancing.\n\nFinally, **Coiled Therapeutics**—formerly Roquefort Therapeutics—experienced early volatility following its move to AIM and the acquisition of cancer treatment candidate **AO-252** in a **£31.9 million share deal**. After an initial dip, the shares recovered to **10p**, in line with its recent **£8.5 million placing**."}